Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 LXEO | Healthcare | $2.87 | 446.91K | $238.88M | -2.50 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc. | 2.87 | -6.17 | -68.25% |
| Name | Price | % Change | |
|---|---|---|---|
| LXEO | $2.87 | -68.25% |
07:37 EDT Lexeo Therapeutics (LXEO) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks
Lexeo Therapeutics, Inc. ( ($LXEO) ) just unveiled an announcement. Lexeo Therapeutics disclosed that it issued shares of its common stock in connection with a merger transaction, relying on exemptions
Lexeo Therapeutics (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia, including the signing of a definitive agreement to acquire Mantle Therapeutics and three new
Lexeo Therapeutics, Inc. ( ($LXEO) ) has issued an announcement. On September 16, 2026, Lexeo Therapeutics agreed to acquire private clinical-stage FA specialist Mantle Therapeutics for $8.3 million in cash
“We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R. Nolan Townsend, Chief Executive
Lexeo Therapeutics, Inc. ( ($LXEO) ) has shared an announcement. On August 12, 2026, Lexeo Therapeutics reported second-quarter 2026 results and detailed progress across its gene therapy portfolio, underscoring a
Meeting to be held in New York on August 13 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See
Lexeo Therapeutics, Inc. ($LXEO) announced an update on their ongoing clinical study. Lexeo Therapeutics Inc. is running a Phase 2 study called SUNRISE-FA 2 to test LX2006 gene therapy in
Biotech Analysts discuss Friedreich’s Ataxia developments from the patient community perspective (relevant companies LRMR SLDB BIIB PTCT LXEO DSGN) on an Analyst/Industry conference call to be held on July 9.
An announcement from Lexeo Therapeutics, Inc. ( ($LXEO) ) is now available. Lexeo Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 25, 2026, where shareholders voted
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| LXEO | Dec 14, 2026TBA | $238.88M | $-0.32 | $0.00 | 0.13 | -2.50 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
